Nature Communications (Jun 2021)
Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia
- Veronika Ecker,
- Martina Stumpf,
- Lisa Brandmeier,
- Tanja Neumayer,
- Lisa Pfeuffer,
- Thomas Engleitner,
- Ingo Ringshausen,
- Nina Nelson,
- Manfred Jücker,
- Stefan Wanninger,
- Thorsten Zenz,
- Clemens Wendtner,
- Katrin Manske,
- Katja Steiger,
- Roland Rad,
- Markus Müschen,
- Jürgen Ruland,
- Maike Buchner
Affiliations
- Veronika Ecker
- Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
- Martina Stumpf
- Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
- Lisa Brandmeier
- Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
- Tanja Neumayer
- Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
- Lisa Pfeuffer
- Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
- Thomas Engleitner
- TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich
- Ingo Ringshausen
- Wellcome/MRC Cambridge Stem Cell Institute and Department of Haematology, Jeffrey Cheah Biomedical Centre, University of Cambridge
- Nina Nelson
- Institute of Biochemistry and Signal Transduction, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf
- Manfred Jücker
- Institute of Biochemistry and Signal Transduction, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf
- Stefan Wanninger
- Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
- Thorsten Zenz
- Department of Medical Oncology and Hematology, University Hospital and University of Zurich
- Clemens Wendtner
- Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians University (LMU)
- Katrin Manske
- Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München
- Katja Steiger
- Institute of Pathology, Technische Universität München
- Roland Rad
- TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich
- Markus Müschen
- Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine
- Jürgen Ruland
- Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
- Maike Buchner
- Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
- DOI
- https://doi.org/10.1038/s41467-021-23752-2
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 17
Abstract
Current therapeutic approaches in chronic lymphocytic leukemia (CLL) focus on the suppression of PI3K/AKT signaling. Here, the authors show that CLL cells are vulnerable to hyperactivation of the PI3K/AKT signaling pathway and suggest this as a promising concept for CLL therapy.
